Entity Details

Primary name SCN4A_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP35499
EntryNameSCN4A_HUMAN
FullNameSodium channel protein type 4 subunit alpha
TaxID9606
Evidenceevidence at protein level
Length1836
SequenceStatuscomplete
DateCreated1994-06-01
DateModified2021-06-02

Ontological Relatives

GenesSCN4A

GO terms

Show/Hide Table
GOName
GO:0001518 voltage-gated sodium channel complex
GO:0005244 voltage-gated ion channel activity
GO:0005248 voltage-gated sodium channel activity
GO:0005887 integral component of plasma membrane
GO:0006814 sodium ion transport
GO:0006936 muscle contraction
GO:0019228 neuronal action potential
GO:0030424 axon
GO:0034765 regulation of ion transmembrane transport
GO:0035725 sodium ion transmembrane transport
GO:0086010 membrane depolarization during action potential
GO:0100001 regulation of skeletal muscle contraction by action potential

Subcellular Location

Show/Hide Table
Subcellular Location
Cell membrane

Domains

Show/Hide Table
DomainNameCategoryType
IPR000048 IQ motif, EF-hand binding siteSiteBinding site
IPR001696 Voltage gated sodium channel, alpha subunitFamilyFamily
IPR005821 Ion transport domainDomainDomain
IPR008052 Voltage gated sodium channel, alpha-4 subunit, mammalianFamilyFamily
IPR010526 Sodium ion transport-associatedDomainDomain
IPR027359 Voltage-dependent channel domain superfamilyFamilyHomologous superfamily
IPR043203 Voltage-gated cation channel calcium and sodiumFamilyFamily
IPR044564 Voltage-gated sodium channel alpha subunit, inactivation gateDomainDomain

Diseases

Show/Hide Table
Disease IDSourceNameDescription
170500 OMIMPeriodic paralysis hyperkalemic (HYPP)An autosomal dominant channelopathy characterized by episodic flaccid generalized muscle weakness associated with high levels of serum potassium. Concurrence of myotonia is found in HYPP patients. The disease is caused by variants affecting the gene represented in this entry.
170500 OMIMPeriodic paralysis hyperkalemic (HYPP)An autosomal dominant channelopathy characterized by episodic flaccid generalized muscle weakness associated with high levels of serum potassium. Concurrence of myotonia is found in HYPP patients. The disease is caused by variants affecting the gene represented in this entry.
168300 OMIMParamyotonia congenita of von Eulenburg (PMC)An autosomal dominant channelopathy characterized by myotonia, increased by exposure to cold, intermittent flaccid paresis, not necessarily dependent on cold or myotonia, lability of serum potassium, non-progressive nature and lack of atrophy or hypertrophy of muscles. In some patients, myotonia is not increased by cold exposure (paramyotonia without cold paralysis). Patients may have a combination phenotype of PMC and HYPP. The disease is caused by variants affecting the gene represented in this entry.
608390 OMIMMyotonia SCN4A-related (MYOSCN4A)A phenotypically highly variable myotonia aggravated by potassium loading, and sometimes by cold. Myotonia is characterized by sustained muscle tensing that prevents muscles from relaxing normally. It causes muscle stiffness that can interfere with movement. In some people the stiffness is very mild, while in other cases it may be severe enough to interfere with walking, running, and other activities of daily life. Myotonia SCN4A-related includes myotonia permanens and myotonia fluctuans. In myotonia permanens, the myotonia is generalized and there is a hypertrophy of the muscle, particularly in the neck and the shoulder. Attacks of severe muscle stiffness of the thoracic muscles may be life threatening due to impaired ventilation. In myotonia fluctuans, the muscle stiffness may fluctuate from day to day, provoked by exercise. The disease is caused by variants affecting the gene represented in this entry.
613345 OMIMPeriodic paralysis hypokalemic 2 (HOKPP2)An autosomal dominant disorder manifested by episodic flaccid generalized muscle weakness associated with falls of serum potassium levels. The disease is caused by variants affecting the gene represented in this entry.
614198 OMIMMyasthenic syndrome, congenital, 16 (CMS16)A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness. CMS16 is characterized by fatigable generalized weakness and recurrent attacks of respiratory and bulbar paralysis since birth. The fatigable weakness involves lid-elevator, external ocular, facial, limb and truncal muscles and an decremental response of the compound muscle action potential on repetitive stimulation. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB00243 RanolazineDrugbanksmall molecule
DB00273 TopiramateDrugbanksmall molecule
DB00281 LidocaineDrugbanksmall molecule
DB00313 Valproic acidDrugbanksmall molecule
DB00555 LamotrigineDrugbanksmall molecule
DB00564 CarbamazepineDrugbanksmall molecule
DB00586 DiclofenacDrugbanksmall molecule
DB00776 OxcarbazepineDrugbanksmall molecule
DB00818 PropofolDrugbanksmall molecule
DB00907 CocaineDrugbanksmall molecule
DB00909 ZonisamideDrugbanksmall molecule
DB01069 PromethazineDrugbanksmall molecule
DB01195 FlecainideDrugbanksmall molecule
DB05541 BrivaracetamDrugbanksmall molecule
DB09085 TetracaineDrugbanksmall molecule
DB09088 AmylocaineDrugbanksmall molecule
DB09342 PropoxycaineDrugbanksmall molecule
DB09345 PramocaineDrugbanksmall molecule
DB11186 PentoxyverineDrugbanksmall molecule
DB13154 ParachlorophenolDrugbanksmall molecule
DB13269 Dichlorobenzyl alcoholDrugbanksmall molecule
DB13746 BioallethrinDrugbanksmall molecule
DB13961 Fish oilDrugbankbiotech